Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.78|
|52 Week High||AU$1.55|
|52 Week Low||AU$3.45|
|1 Month Change||0.28%|
|3 Month Change||5.95%|
|1 Year Change||-21.59%|
|3 Year Change||72.82%|
|5 Year Change||49.58%|
|Change since IPO||-5.07%|
Recent News & Updates
Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates
One thing we could say about the covering analyst on Cyclopharm Limited ( ASX:CYC ) - they aren't optimistic, having...
Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being
The share price of Cyclopharm Limited ( ASX:CYC ) has increased significantly over the past few years. However, the...
|CYC||AU Medical Equipment||AU Market|
Return vs Industry: CYC underperformed the Australian Medical Equipment industry which returned -4.9% over the past year.
Return vs Market: CYC underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: CYC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CYC's weekly volatility (7%) has been stable over the past year.
About the Company
Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. It offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism.
Cyclopharm Fundamentals Summary
|CYC fundamental statistics|
Is CYC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CYC income statement (TTM)|
|Cost of Revenue||AU$4.74m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.046|
|Net Profit Margin||-21.19%|
How did CYC perform over the long term?See historical performance and comparison
0.6%Current Dividend Yield
Is Cyclopharm undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CYC (A$1.78) is trading above our estimate of fair value (A$0.04)
Significantly Below Fair Value: CYC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CYC is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: CYC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CYC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CYC is good value based on its PB Ratio (3.7x) compared to the AU Medical Equipment industry average (4.5x).
How is Cyclopharm forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CYC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CYC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CYC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CYC's revenue (11.4% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: CYC's revenue (11.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CYC is forecast to be unprofitable in 3 years.
How has Cyclopharm performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CYC is currently unprofitable.
Growing Profit Margin: CYC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CYC is unprofitable, and losses have increased over the past 5 years at a rate of 63.4% per year.
Accelerating Growth: Unable to compare CYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: CYC has a negative Return on Equity (-9.75%), as it is currently unprofitable.
How is Cyclopharm's financial position?
Financial Position Analysis
Short Term Liabilities: CYC's short term assets (A$42.3M) exceed its short term liabilities (A$4.7M).
Long Term Liabilities: CYC's short term assets (A$42.3M) exceed its long term liabilities (A$5.3M).
Debt to Equity History and Analysis
Debt Level: CYC is debt free.
Reducing Debt: CYC had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CYC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 54.4% each year
What is Cyclopharm current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CYC's dividend (0.56%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.27%).
High Dividend: CYC's dividend (0.56%) is low compared to the top 25% of dividend payers in the Australian market (5.32%).
Stability and Growth of Payments
Stable Dividend: CYC is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: CYC is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CYC is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CYC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
James McBrayer (56 yo)
Mr. James S. McBrayer, BSPharm, GDM, FAICD, AIM, has been the Managing Director at Cyclopharm Ltd. since June 3, 2008 and also serves as its Chief Executive Officer. Mr. McBrayer has been Company Secretary...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD880.72K) is above average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
Experienced Management: CYC's management team is considered experienced (2.1 years average tenure).
Experienced Board: CYC's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.3%.
Cyclopharm Limited's employee growth, exchange listings and data sources
- Name: Cyclopharm Limited
- Ticker: CYC
- Exchange: ASX
- Founded: 1986
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$166.207m
- Shares outstanding: 93.37m
- Website: https://www.cyclopharm.com.au
Number of Employees
- Cyclopharm Limited
- 1 The Crescent
- Unit 4
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 07:04|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.